1.23
-0.04(-3.15%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.27 |
| Day High | 1.28 |
| Day Low | 1.21 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.7 |
| Volume | 845,130 |
| Average Volume | 598,347 |
| Market Cap | 154.74M |
| PE | -5.86 |
| EPS | -0.21 |
| Moving Average 50 Days | 1.4 |
| Moving Average 200 Days | 1.39 |
| Change | -0.04 |
If you invested $1000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, it would be worth $8.23 as of December 04, 2024 at a share price of $1.23. Whereas If you bought $1000 worth of Atossa Therapeutics, Inc. (ATOS) shares 5 years ago, it would be worth $854.17 as of December 04, 2024 at a share price of $1.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
GlobeNewswire Inc.
Nov 21, 2024 1:30 PM GMT
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast CancerSEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the ant
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Nov 20, 2024 1:30 PM GMT
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at conferenceSEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: AT
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
GlobeNewswire Inc.
Nov 05, 2024 1:30 PM GMT
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa’s Mission in Developing Innovative Breast Cancer TherapiesSEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or th